145 related articles for article (PubMed ID: 17574311)
1. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Wellde BT; White K; Sun P; Schwenk R; Krzych U; Delchambre M; Voss G; Dubois MC; Gasser RA; Dowler MG; O'Brien M; Wittes J; Wirtz R; Cohen J; Ballou WR;
Vaccine; 2007 Jul; 25(29):5359-66. PubMed ID: 17574311
[TBL] [Abstract][Full Text] [Related]
2. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
5. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.
Stoute JA; Heppner DG; Mason CJ; Siangla J; Opollo MO; Kester KE; Vigneron L; Voss G; Walter MJ; Tornieporth N; Cohen JD; Ballou WR
Am J Trop Med Hyg; 2006 Jul; 75(1):166-70. PubMed ID: 16837726
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
Macete EV; Sacarlal J; Aponte JJ; Leach A; Navia MM; Milman J; Guinovart C; Mandomando I; López-Púa Y; Lievens M; Owusu-Ofori A; Dubois MC; Cahill CP; Koutsoukos M; Sillman M; Thompson R; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Trials; 2007 Mar; 8():11. PubMed ID: 17386091
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
Sacarlal J; Aide P; Aponte JJ; Renom M; Leach A; Mandomando I; Lievens M; Bassat Q; Lafuente S; Macete E; Vekemans J; Guinovart C; Sigaúque B; Sillman M; Milman J; Dubois MC; Demoitié MA; Thonnard J; Menéndez C; Ballou WR; Cohen J; Alonso PL
J Infect Dis; 2009 Aug; 200(3):329-36. PubMed ID: 19569964
[TBL] [Abstract][Full Text] [Related]
12. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
Stewart VA; Walsh DS; McGrath SM; Kester KE; Cummings JF; Voss G; Delchambre M; Garçon N; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6493-502. PubMed ID: 16911849
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
Walsh DS; Pichyangkul S; Gettayacamin M; Tongtawe P; Siegrist CA; Hansukjariya P; Kester KE; Holland CA; Voss G; Cohen J; Stewart AV; Miller RS; Ballou WR; Heppner DG
Am J Trop Med Hyg; 2004 May; 70(5):499-509. PubMed ID: 15155981
[TBL] [Abstract][Full Text] [Related]
15. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
[TBL] [Abstract][Full Text] [Related]
18. The RTS,S vaccine candidate for malaria.
Regules JA; Cummings JF; Ockenhouse CF
Expert Rev Vaccines; 2011 May; 10(5):589-99. PubMed ID: 21604980
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
Genton B; D'Acremont V; Lurati-Ruiz F; Verhage D; Audran R; Hermsen C; Wolters L; Reymond C; Spertini F; Sauerwein R
Vaccine; 2010 Sep; 28(40):6573-80. PubMed ID: 20691266
[TBL] [Abstract][Full Text] [Related]
20. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
